Ivím Health Review: It Publishes Real Peer-Reviewed Outcomes — And Locks You Into the Whole Program Term

What Is Ivím Health?

Ivím Health, operated by IVIM Services LLC of Columbus, Ohio, is a membership-based virtual clinic covering weight loss, women's and men's hormone health, and a broad catalogue of supplements and peptides. It has traded since April 2022 and has been BBB accredited with an A+ rating since February 2023. The company reports 470,000 patients served and around 100 board-certified providers, with same-day and unlimited provider visits included in membership.

The weight-loss offering is unusually complete. Unlike providers that funnel everyone toward a compounded product, Ivím lists the branded, FDA-approved drugs — Wegovy, Zepbound, Mounjaro, Ozempic, Saxenda and liraglutide — alongside compounded semaglutide and tirzepatide and a microdosing program. It also carries the Wegovy pill, the oral semaglutide the FDA approved in December 2025, which it accurately describes as the first FDA-approved oral GLP-1 for weight management. Offering the approved product rather than only a compounded imitation of it is worth real credit, and it is the difference between this review and several others in this series.

The membership is the organising idea rather than an add-on, and the company is explicit about that: "your membership isn't a feature or an upgrade. It's how we practice medicine." It buys unlimited provider access, protocol adjustments between visits and continuity of care team. Whether that is worth $75 a month on top of medication is a judgement each reader can make, but it is at least an honest description of what is being sold.

What makes Ivím genuinely different is that it has published outcomes. Two peer-reviewed papers in Obesity Pillars — one on semaglutide covering 1,131 patients over 52 to 68 weeks, one on tirzepatide covering 1,166 patients over 52 to 72 weeks — report the results of its own care model. Almost no telehealth GLP-1 company does this. We spend a great deal of this series noting that providers publish nothing verifiable; here there is something to actually read, and we assess it properly below rather than simply applauding it.

Medications Offered & Pricing

Prices checked on ivimhealth.com on 7 August 2026. The critical thing to understand is that no advertised medication price is your actual monthly cost. The microdosing page shows compounded tirzepatide "$133/mo" on a six-month term, with "+ $74.99/mo Program fee" beneath it — so the real figure is $207.99 a month, or roughly $1,248 across the six months you are committing to. Compounded semaglutide at $75/mo is really $149.99. The Wegovy pill at its $299 maintenance price is $374 a month once membership is added. To the company's credit the fee is disclosed on the same page rather than hidden at checkout, but it is presented as a footnote to a headline number that is 36% lower than the truth. Note too that the cheapest per-month rates require the longest commitments, and that those commitments are not cancellable — see below.

Brand-Name or Compounded?

Ivím's disclosure on compounding is better than most, and we want to say so before raising the difficulty. Its product pages carry plain language: "While federal law allows the prescription of compounded drugs, they are not FDA-approved and do not undergo FDA review for safety, efficacy, or quality." The microdosing page repeats it. That is the correct disclosure and many competitors bury or omit it.

The regulatory context has changed substantially, though, and it applies to every provider still selling compounded GLP-1s. The FDA declared the tirzepatide shortage resolved in December 2024, after removing it from the shortage list in October, reconsidering, then reaffirming. Enforcement discretion for 503A state-licensed pharmacies compounding tirzepatide injection products ended on 18 February 2025, and for 503B outsourcing facilities on 19 March 2025. The semaglutide shortage was declared resolved in February 2025, with the equivalent 503A deadline on 22 April 2025 and the 503B deadline on 22 May 2025. Then, in a notice published on 1 May 2026 with comments closing 29 June 2026, the FDA proposed not to include semaglutide, tirzepatide or liraglutide on the 503B bulks list at all, having found no clinical need for outsourcing facilities to compound them from bulk substances.

Compounding a drug that is commercially available is lawful under section 503A only where the preparation is not essentially a copy of the approved product — which generally requires a documented clinical need for the individual patient, such as a different dose or the removal of an ingredient they cannot tolerate. Ivím's framing gestures at this: it describes "customized compounded solutions individualized to your needs" and sells a microdosing program built around doses below the standard titration schedule. Personalised dosing is the strongest available basis for compounding these drugs now, and a microdosing program is a more coherent version of that argument than most. We are not in a position to adjudicate whether it succeeds, and we are not suggesting anything improper. We are telling you that the legal footing for compounded GLP-1s is materially less certain than it was in 2024, that the FDA has signalled it intends to narrow it further, and that a six-month non-cancellable commitment to a compounded product carries a supply risk you should factor in.

There is a straightforward way to sidestep the whole question, and Ivím already offers it. The FDA approved Wegovy tablets in December 2025, and the label states that in patients without type 2 diabetes, average semaglutide blood concentrations on 25mg once daily and on the 2.4mg weekly injection were similar. If you want semaglutide without needles and without the compounding question, the approved pill exists and Ivím sells it. It costs more — $149 rising to $299 a month plus membership, against $75 plus fee for compounded — and for many people the price difference will decide it. That is a legitimate reason to choose compounded. It is a different reason from believing the two are equivalent products, and they are not: one has been reviewed by the FDA for safety and effectiveness and the other has not.

One further note on the wider catalogue. Ivím sells compounded sermorelin and markets it as something that "may have anti-aging benefits and may also help to improve libido and sexual performance," alongside a longevity line including NAD+, NMN and colostrum. Those are claims well ahead of their evidence, and they sit oddly beside the company's otherwise careful approach to its GLP-1 data. If you join for weight care, treat the peptide and longevity upsells as a separate proposition and apply more scepticism to them than the weight-loss program has earned.

The Consultation Process

Eligibility

• •A clinical evaluation by an Ivím provider is required before any prescription, and the company states medication is provided "only if deemed medically appropriate."
• •Hormone health programs require baseline laboratory testing, which Ivím positions as a requirement rather than an option — a good sign for a category where some competitors skip it.
• •Specific published BMI or comorbidity thresholds for the weight programs were not disclosed on the pages we reviewed.
• •State availability is not published in a consolidated list on the pages we reviewed; the company operates nationwide but confirm your state before committing to a term.
• •Membership is required to access any medication — there is no medication-only purchase path.

Provider Involvement, Labs & Pharmacy

Shipping & Support Services

Medication delivery details, including carriers and cold-chain handling, were not published in detail on the pages we reviewed. Ivím publishes injection instructions and a medication safety information page, both of which are useful and more than many competitors provide. If cold-chain handling matters to you — and for GLP-1s it does — ask before committing to a multi-month term.

• •Support runs through the website, email to support@ivimhealth.com, and text. Unlimited same-day provider visits are the headline service claim, and the membership model is explicitly built around access between appointments rather than at scheduled intervals.
• •The company's public record is good. IVIM Services LLC has been BBB accredited since 28 February 2023 and holds an A+ rating, having traded since 29 April 2022. In a sector where we routinely find D-grade ratings and unanswered complaints, that is a meaningful differentiator and we weight it accordingly.
• •Resource provision is above average: a resource centre, blog, webinars, published injection instructions, medication safety information and a dedicated Klarna FAQ. The company also runs a corporate program.
• •Against that, several pages linked in the site's own navigation returned 404 errors when we checked on 7 August 2026, including Our Providers, the returns policy and a pricing page. For a company asking for a six-month non-refundable commitment, broken links to the pages describing its clinicians and its returns terms are the wrong pages to have broken.

Fees, Cancellation & Refunds

Insurance & HSA/FSA

Pros & Cons

Who Ivím Health May Be Best For

• •People who want a provider that publishes outcomes and can be checked, rather than one that asserts them
• •Patients who want the FDA-approved Wegovy pill with clinical support wrapped around it
• •People who value continuous access to a provider between appointments and will actually use it
• •Patients who may be able to get a branded GLP-1 through insurance and want help pursuing that
• •Anyone confident they will stay on treatment for the full term they select
• •People who want hormone care with mandatory baseline labs rather than a questionnaire

Limitations

• •The contract is the limitation. No mid-term cancellation on a class of medication that a meaningful minority of patients discontinue for gastrointestinal side effects means the foreseeable risk sits entirely with you. If you are new to GLP-1s and do not yet know how you tolerate them, a six-month non-refundable term is the wrong shape of commitment, however good the per-month price looks.
• •Advertised pricing is not real pricing. Every medication figure on the site excludes the mandatory program fee. The fee is disclosed on the same page, so this is not concealment, but a $133 headline attached to a $207.99 reality is a presentation choice, and it recurs across the catalogue.
• •The research needs reading carefully, and this cuts both ways. Publishing two peer-reviewed papers on 2,297 patients puts Ivím far ahead of its competitors and we do not want to undersell that. But observational real-world cohorts count the patients who stayed on treatment and kept returning. Randomised trials like SURMOUNT-1 and STEP use intention-to-treat analyses that include everyone who dropped out. A completer cohort will beat an ITT trial almost by construction, which is the likely explanation for 26.5% against SURMOUNT-1's 20.9%. Ivím's research page says as much. Its press releases, which claim "nearly 50% greater weight loss," do not.
• •Compounded GLP-1s now rest on the individualisation argument rather than on a shortage listing, and the FDA has proposed narrowing the 503B route further. A microdosing program is a better-founded version of that argument than most, but a long non-cancellable commitment to a compounded product carries a supply risk that a commitment to an approved product does not.
• •The peptide and longevity line — sermorelin, NAD+, NMN, colostrum — is marketed with claims well beyond its evidence, and the sermorelin copy in particular reaches for anti-aging and sexual performance benefits. That range should not borrow the credibility the weight-loss program has earned.
• •Broken navigation links to the providers page and the returns policy are minor in isolation but poorly placed: those are precisely the pages a prospective patient should read before accepting a non-refundable multi-month agreement.

Alternatives to Consider

Frequently Asked Questions

Our Verdict

Ivím is one of the better-run companies we have reviewed in this category, and the reason is that it can be checked. It published two peer-reviewed papers in Obesity Pillars on more than 2,200 of its own patients. It holds an A+ BBB accreditation dating to 2023. It employs around 100 board-certified providers, requires baseline labs for hormone care, discloses the limits of compounded medication in plain language, and sells the FDA-approved Wegovy pill rather than insisting everyone take a compounded imitation. Most of this series is spent asking providers to do those things. This one has.

It also, to its considerable credit, prints the caveat on its own research page: "These are not head-to-head randomized controlled trials and should not be interpreted as such." That sentence is the difference between presenting evidence and spinning it, and we would rather see it than not. The company's press releases are less disciplined — "nearly 50% greater weight loss" is precisely the interpretation the research page warns against, and the gap between a completer cohort and an intention-to-treat trial is the likely explanation for most of the difference.

The problems are commercial and they are real. Every medication price on the site excludes a mandatory $74.99 monthly program fee, so the advertised $133 tirzepatide is $207.99 and the $75 semaglutide is $149.99. And the membership agreement provides no mid-term cancellation: you owe the full term you select "regardless of usage or early cancellation," with all fees non-refundable once accepted. Those two terms interact badly. The best per-month price requires the longest lock-in, and the longest lock-in is the one you cannot leave — on a class of drug where a real share of patients stop because of nausea and vomiting within the first weeks.

So the practical advice is specific. If you are new to GLP-1s, do not take the six-month deal for the headline price. Take the shortest term available, find out how you tolerate the medication, and extend once you know. If you can access a branded drug through insurance, Ivím is unusually willing to help you pursue that and you should ask. If you want to avoid the compounding question entirely, the approved Wegovy pill is on the same menu — more expensive, but reviewed by the FDA, which the compounded product is not. And whatever you choose, diarise the renewal date, because you need to give notice 48 hours ahead of it.

Rated 3.6 out of 5. A serious clinical operation with published evidence and a real track record, held back by pricing that understates itself and a contract that transfers an entirely predictable risk onto the patient. Fix the cancellation terms and this would be among the highest-rated providers in this series.